Opinion|Videos|September 18, 2024
Fruquintinib in mCRC: Key Insights From FRESCO-2
Medical experts highlight key data from the FRESCO-2 trial on fruquintinib for previously treated metastatic colorectal cancer, focusing on study population, efficacy, and safety, and discuss real-world experience with fruquintinib compared with trial outcomes.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- New to our arsenal of drugs is fruquintinib, an additional option for previously treated metastatic colorectal cancer based on the FRESCO-2 data. What are some highlights of this data in terms of the study population, efficacy, and safety?
- Include in this discussion that all patients previously received regorafenib or FTD/TPI.
- What has been your experience using fruquintinib in practice, and how do patient outcomes compare with what was seen in FRESCO-2?
Advertisement
Related to this article
The triple agonist also lowered HbA1C by up to 1.6% over 80 weeks, with up to 40% of participants reaching normal levels.
A network meta-analysis found vibegron outperformed mirabegron and tolterodine on several OAB efficacy measures but had higher odds of adverse events.
A US modeling study found tirzepatide and semaglutide cost-effective for MASH, while resmetirom exceeded the $100,000/QALY threshold.
Expert panel discussions covered AI and community access, chronic lymphocytic leukemia, myeloma, and breast and lung cancers.
The analysis found a nonlinear association between systemic inflammation and overactive bladder, with stronger links at higher inflammation levels.
A real-world study found that adding a GLP-1 to SGLT2 inhibitor therapy was associated with lower kidney, cardiovascular, and mortality risks in CKD.
In experiments at MD Anderson, rising CD70 helps mantle cell lymphoma evade immunity; a CD70×CD3 bispecific restores T-cell killing and prolongs survival in resistant models.
Upper-extremity synovial sarcoma required more staged surgery, while lower-extremity disease carried more complications and metastases.
Advertisement
Advertisement
Trending on AJMC
1
IRA, 340B, Medicaid: The Policy Pressures on Community Oncology
2
Drug Price Drives Value of MASH Therapies More Than Efficacy
3
Vibegron Outranks Mirabegron, Tolterodine on Several OAB Measures
4
Boston Experts Weigh Access, Sequencing, and Testing Across 4 Cancers
5